NYSEAMERICAN:ISR - Isoray Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $1.84
  • Forecasted Upside: 176.40 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$0.66
▲ +0.0123 (1.89%)

This chart shows the closing price for ISR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Isoray Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ISR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ISR

Analyst Price Target is $1.84
▲ +176.40% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Isoray in the last 3 months. The average price target is $1.84, with a high forecast of $3.00 and a low forecast of $1.00. The average price target represents a 176.40% upside from the last price of $0.66.

This chart shows the closing price for ISR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 investment analysts is to buy stock in Isoray. This rating has held steady since November 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/6/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/5/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/3/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/1/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/1/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/30/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/29/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/28/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/14/2021Northland SecuritiesInitiated CoverageOutperform$1.25
2/18/2021Lake Street CapitalInitiated CoverageBuy$3.00
2/10/2021HC WainwrightBoost Price TargetBuy$1.25 ➝ $2.10
12/16/2020OppenheimerInitiated CoverageOutperform$1.00
12/15/2020OppenheimerInitiated CoverageOutperform$1.00
11/12/2020HC WainwrightReiterated RatingBuy$1.25
10/20/2020Dawson JamesDowngradeBuy ➝ Neutral
5/15/2020Ascendiant Capital MarketsBoost Price TargetBuy$1.40 ➝ $1.75
2/12/2020HC WainwrightReiterated RatingBuy$0.70 ➝ $1.25
7/1/2019Dawson JamesInitiated CoverageBuy
5/13/2019HC WainwrightReiterated RatingBuy$0.70
2/14/2019HC WainwrightSet Price TargetBuy$1.00
1/28/2019HC WainwrightReiterated RatingBuy
11/13/2018HC WainwrightSet Price TargetHold$1.00
11/9/2018Maxim GroupDowngradeBuy ➝ Hold
9/26/2018HC WainwrightSet Price TargetHold$1.00
9/26/2018Maxim GroupReiterated RatingBuy$2.00
8/20/2018HC WainwrightReiterated RatingNeutral
8/20/2018HC WainwrightInitiated CoverageNeutral$1.00
5/4/2018Maxim GroupSet Price TargetBuy$2.00
4/2/2018Ascendiant Capital MarketsInitiated CoverageBuy$1.00
2/14/2018Maxim GroupSet Price TargetBuy ➝ Buy$3.00 ➝ $2.00
2/8/2018Maxim GroupSet Price TargetBuy$3.00 ➝ $2.00
1/24/2018Maxim GroupSet Price TargetBuy$3.00
11/15/2017Maxim GroupSet Price TargetBuy$3.00
9/28/2017Maxim GroupReiterated RatingBuy$3.00
7/6/2017Maxim GroupSet Price TargetBuy$3.00
5/11/2017Maxim GroupSet Price TargetBuy$3.00
(Data available from 9/28/2016 forward)

News Sentiment Rating

-0.07 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
3/2/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/1/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/30/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/29/2021
  • 0 very positive mentions
  • 19 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
9/28/2021

Current Sentiment

  • 0 very positive mentions
  • 19 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
Isoray logo
IsoRay, Inc. is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The company focuses on the treatment of cancer and other malignant diseases. Its core product is Cesium-131, a radioisotope for the treatment of malignant tumors. The company was founded by Lance A. Bray in 1983 and is headquartered in Richland, WA.
Read More

Today's Range

Now: $0.66
Low: $0.65
High: $0.69

50 Day Range

MA: $0.45
Low: $0.38
High: $0.54

52 Week Range

Now: $0.66
Low: $0.35
High: $2.81

Volume

3,068 shs

Average Volume

6,142,651 shs

Market Capitalization

$94.05 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.02

Frequently Asked Questions

What sell-side analysts currently cover shares of Isoray?

The following Wall Street analysts have issued stock ratings on Isoray in the last twelve months: Dawson James, HC Wainwright, Lake Street Capital, Northland Securities, Oppenheimer Holdings Inc., and Zacks Investment Research.
View the latest analyst ratings for ISR.

What is the current price target for Isoray?

4 Wall Street analysts have set twelve-month price targets for Isoray in the last year. Their average twelve-month price target is $1.84, suggesting a possible upside of 181.6%. Lake Street Capital has the highest price target set, predicting ISR will reach $3.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $1.00 for Isoray in the next year.
View the latest price targets for ISR.

What is the current consensus analyst rating for Isoray?

Isoray currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ISR will outperform the market and that investors should add to their positions of Isoray.
View the latest ratings for ISR.

What other companies compete with Isoray?

How do I contact Isoray's investor relations team?

Isoray's physical mailing address is 350 Hills St Ste 106, RICHLAND, WA 99354-5511, United States. The healthcare company's listed phone number is (509) 375-1202 and its investor relations email address is [email protected] The official website for Isoray is isoray.com.